IQVIA Holdings Inc. (NYSE:IQV – Get Free Report) has been given an average rating of “Buy” by the seventeen brokerages that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $224.1250.
IQV has been the topic of a number of recent analyst reports. Weiss Ratings downgraded shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Barclays upgraded shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target on the stock in a research report on Friday, March 6th. HSBC set a $210.00 price target on shares of IQVIA in a research report on Wednesday, June 3rd. Truist Financial dropped their price target on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research report on Thursday, February 19th. Finally, Mizuho set a $215.00 price target on shares of IQVIA in a research report on Monday, February 23rd.
View Our Latest Stock Analysis on IQVIA
IQVIA Stock Performance
IQVIA (NYSE:IQV – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The firm had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Research analysts anticipate that IQVIA will post 11.6 earnings per share for the current year.
IQVIA announced that its Board of Directors has authorized a share buyback program on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s board believes its stock is undervalued.
Institutional Investors Weigh In On IQVIA
Hedge funds have recently added to or reduced their stakes in the business. Ameliora Wealth Management Ltd. bought a new stake in IQVIA in the fourth quarter worth approximately $25,000. International Assets Investment Management LLC bought a new stake in IQVIA in the fourth quarter worth approximately $27,000. Gilpin Wealth Management LLC bought a new stake in IQVIA in the fourth quarter worth approximately $27,000. CrossGen Wealth LLC bought a new stake in IQVIA in the fourth quarter worth approximately $28,000. Finally, Activest Wealth Management increased its holdings in IQVIA by 590.0% in the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after purchasing an additional 118 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.
About IQVIA
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Recommended Stories
- Five stocks we like better than IQVIA
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
